Trial Profile
Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome (AML19): a randomised, controlled, open label Phase III trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Ganetespib (Primary) ; Gemtuzumab ozogamicin (Primary) ; Midostaurin (Primary) ; Cytarabine; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms AML-19
- 12 Dec 2023 Results assessing comprehensive genotyping and molecular MRD assessment in two consecutive prospective randomised studies (NCRI AML17 (2009-2014) and AML19 (2015-2020)) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 10 Dec 2023 According to an American Society of Hematology media release, data from this study are being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight, by Jad Othman.
- 10 Dec 2023 Results presented in an American Society of Hematology media release.